JPRN-jRCTs041180070进行中（未招募）未知
Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS
Ouchi Yasuomi0 个研究点目标入组 20 人开始时间: 2019年3月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 < 80age old（—）
- 性别
- All
入选标准
- •Inclusion criteria are following
- •1) Early Parkinson's disease patients medicated once with levodopa/DCI and other anti-parkinsonian drugs excluding zonisamide
- •2) Patients under 80 years old
- •3) Patients who have voluntarily provided written informed consent to participate in the study
排除标准
- •Exclusion criteria are following
- •1) Patients with parkinsonism except Parkinson's disease
- •2) Patients with epilepsy
- •3) Patients with a history of surgery for Parkinson's disease within 6 months before screening
- •4) Patients treated with zonisamide, selegiline and/or pramipexole within 3 months before screening
- •5) Patients with any severe psychiatric symptoms, such as confusion, hallucination, delusion and abnormal behaviors
- •6) Patients with any histories of malignant syndrome
- •7) Patients with a history of drug allergy for zonisamide
- •8) Patients participating any other clinical studies (intervention) when screening
- •9,10) Patients evaluated as unsuitable for participation in the study by physicians
研究者
相似试验
已完成
不适用
Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesParkinson's DiseaseJPRN-UMIN000019524Hamamatsu University School of Medicine20
尚未招募
3 期
Comparative Study of the Efficacy and Safety of Budesonide, Inhalation Powder, Capsule 400 μg/doseCTRI/2017/02/007787Rus Biopharm LLC136
进行中（未招募）
不适用
An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in the treatment of elderly patients (aged ≥ 65 years) with complicated Skin and Soft Tissue Infections (cSSTIs) - NDComplicated skin and soft tissue infectionsEUCTR2009-014391-22-ITovartis Pharma AG146
进行中（未招募）
不适用
An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in the treatment of elderly patients (aged = 65 years) with complicated Skin and Soft Tissue Infections (cSSTIs)complicated skin and soft tissue infections.EUCTR2009-014391-22-DEovartis Pharma AG146
进行中（未招募）
不适用
An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in the treatment of elderly patients (aged = 65 years) with complicated Skin and Soft Tissue Infections (cSSTIs)complicated skin and soft tissue infections.EUCTR2009-014391-22-ATovartis Pharma Services AG146